RAYNAUD PHENOMENON - ITS RELEVANCE TO SCLERODERMA

RAYNAUD PHENOMENON - ITS RELEVANCE TO SCLERODERMA
复制标题

DOI:
10.1136/ard.50.suppl_4.839
复制
发表时间:
1991-11-01
影响因子:
27.4
通讯作者:
BELCH, JJF
BELCH, JJF
中科院分区:
医学1区
文献类型:
--
作者:
BELCH, JJF

文献摘要

被引文献

相似文献

自Maurice Raynaud首次描述他的临床综合征以来,已经过去了125年。根据定义,它是由寒冷和情绪引起的间歇性指缺血。典型的表现是受影响部位的苍白,随后是发绀和发红。苍白反映血管痉挛,发绀是由于静止的静脉血中的氧被除去,而发红则是血流恢复后的反应性充血。雷诺现象的总体患病率约为10%,2尽管它可能影响多达20-30%的年轻女性。虽然它可能是一种良性疾病(原发性雷诺病),但它可能与潜在疾病(雷诺综合征)有关。它特别与结缔组织疾病有关(表1)。雷诺氏综合征发生在90%至98%的系统性硬化症患者中,4更重要的是,雷诺氏综合征被证明是700/o的这种疾病患者的首发症状4 5,并且可能在其发展之前长达20年。6在这篇综述中,建议从两个方面评估雷诺现象与系统性硬化症的相关性。首先,通过报告医学部,证据支持雷诺现象作为Nineweils医院,系统性硬化症的前兆,其次,通过讨论其作为一个复杂的JJ F打嗝症状在完全建立系统性硬化症的重要性,indee DD 1 9 SY。
It is now over 125 years since Maurice Raynaud first described his clinical syndrome.'By definition, it is episodic digital ischaemia provoked by cold and emotion. It is classically manifest by pallor of the affected part followed by cyanosis and rubor. The pallor reflects vasospasm, the cyanosis results from removal of oxygen from the static venous blood, and rubor is caused by reactive hyperaemia following return of flow. Raynaud's phenomenon has an overall prevalence of about 10%, 2 though it may affect as many as 20-30% of younger women. 3 Although it can be a benign condition (primary Raynaud's disease), it may be associated with an underlying disorder (Raynaud's syndrome). It is particularly associated with the connective tissue diseases (table 1). Raynaud's syndrome occurs in between 90 and 98% of patients with systemic sclerosis, 4 and more importantly proves to be the first symptom in700/o of patients with this disease4 5 and may precede its development by up to 20 years. 6 In this review it is proposed to evaluate the relevance of Raynaud's phenomenon to systemic sclerosis in two ways. Firstly, by reporting the Department ofMedicine, evidence supporting Raynaud's phenomenon as Nineweils Hospital, a precursor of systemic sclerosis and, secondly, indee DD1 9SY by discussing its importance as a complicating JJ F Belch symptom in fully established systemic sclerosis.